Curated News
By: NewsRamp Editorial Staff
January 20, 2024
New Brain Institute Introduces SPRAVATO™ Ketamine Therapy for Treatment-Resistant Depression
TLDR
- SPRAVATO™ offers a superior solution for treatment-resistant depression, giving patients an advantage over traditional antidepressant medications.
- SPRAVATO™ is a nasal spray administered at New Brain Institute twice a week for four weeks, followed by weekly sessions for one month.
- SPRAVATO™ is a game-changer in mental health care, providing hope to patients who have not found relief from traditional antidepressants.
- SPRAVATO™, a ketamine-based therapy, is emerging as a transformative and promising solution for those struggling with depression.
Impact - Why it Matters
The introduction of SPRAVATO™ by New Brain Institute is significant as it provides a novel approach to treating depression for patients who have not found relief with traditional antidepressants. This therapy offers hope and a potential game-changer in mental health care, with minimal side effects and extensive monitoring by healthcare professionals to ensure patient safety and well-being.
Summary
New Brain Institute introduces SPRAVATO™, an FDA-approved ketamine therapy for treatment-resistant depression in adults. The nasal spray is administered in the institute's state-of-the-art treatment center and offers hope to patients who have not found relief from traditional antidepressant medications. The treatment involves strict medical supervision and has demonstrated superior efficacy compared to traditional pharmaceuticals, making it a promising solution for those struggling with depression.
Source Statement
This curated news summary relied on this press release disributed by Newsworthy.ai. Read the source press release here, New Brain Institute Introduces SPRAVATO™ Ketamine Therapy for Treatment-Resistant Depression
